Drug Profile

LABP 66

Alternative Names: LABP-66; NX-66

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Landos Biopharma
Class Anti-inflammatories; Antidementias; Small molecules
Mechanism of Action NLR protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Alzheimer's disease; Multiple sclerosis
No development reported Encephalomyelitis

Most Recent Events

28 Feb 2025 No recent reports of development identified for preclinical development in Encephalomyelitis in USA (PO)
23 May 2024 Landos Biopharma has been acquired by AbbVie
21 Mar 2024 Landos Biopharma has patents pending for LABP 66 in Australia, Brazil, Canada, Chile, China, Europe, Hong Kong, India, Israel, Japan, Mexico, New Zealand, and South Korea

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com